FDG-PET in clinical oncology: Review of the literature and report of one institution's experience

Journal of Investigative Medicine

Volumn 47, Issue 9, 1999, Pages 452-461

  Oehr, Peter ^a,b   Ruhlmann, Jürgen ^a   Biersack, Hans Jürgen ^a  

^a UNIVERSITY OF BONN   (Germany)

^b PET Center   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; METHODOLOGY; NEOPLASM; ONCOLOGY; REVIEW; SCINTISCANNING;

FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MEDICAL ONCOLOGY; NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033227390     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
2. Blessing C, Feine U, Geiger L, Carl M, Rassner G, Fierlbeck G. Positron emission tomography and ultrasonography - a comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch Dermatol 1995;131:1394-8.
3. Fornage BD, Lorigan JG. Sonographic detection and fine-needle aspiration biopsy of nonpalpable recurrent or metastatic melanoma in subcutaneous tissues. J Ultrasound Med 1989;8:421-4.
4. Haubold-Reuter BG, Duewell S, Schilcher BR, Marincek B, von Schulthess GK. The value of bone scintigraphy and fast spin-echo magnetic resonance imaging in staging of patients with malignant solid tumors: a prospective study. Eur J Nucl Med 1993;20:1063-9.
5. Buzaid AC, Sandler AB, Mani S, Curtis A, Poo WJ, Bolognia JL, Ariyan S. Role of computed tomography in the staging of malignant melanoma. J Clin Oncol 1993;11:638-43.
6. Sasaki M, Ichiya Y, Kuwabara Y, Akashi Y, Yoshida T, Fukumura T, Murayama S, Ishida T, Sugio K, Masuda K. The usefulness of FDG positron emission tomography for the detection of lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography. Eur J Nucl Med 1996;23:741-7.
7. Scott WJ, Gobar LS, Terry JD, Dewan NA, Sunderland JJ. Mediastinal lymph node staging of non-small cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thor Cardiovasc Surg 1996;111:642-8.
8. Kirgan D, Guenther J, Bhattathiry M, et al. The importance of whole body PET scans on the management of metastatic malignant melanoma [abstract]. Program of the Proceedings of the Annual Meeting of the American Society of Clinical Oncology 1994;13:396.
9. Adler LP, Crowe JP, AI-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with (F-18)2-deoxy-2-fluoro-D-glucose PET. Radiology 1993;187:743-50.
10. Böni R Huch-Böni RA, Steinert H, Burg G, Buck A, Marincek B, Berthold T, Dummer R, Voelly D, Ballmer B. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br J Dermatol 1995;132:556-62.
11. Böni R. Whole-body positron emission tomography: an accurate staging modality for metastatic melanoma. Arch Dermatol 1996;132:833-4.
12. Böni R, Huch-Böni RA, Steinert H, von Schulthess GK, Burg G. Early detection of melanoma metastasis using fluorodeoxyglucose F-18 positron emission tomography. Arch Dermatol 1996;132:875-6.
13. Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-d-glucose in the imaging of malignant melanoma. J Nucl Med 1993;34:1420-7.
14. Grünwald F, Schomburg A, Bender H, Klemm E, Menzel C, Bultmann T, Palmedo H, Ruhlman J, Kozak B, Biersack HJ. Fluorine-18-fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1996;23:312-9.
15. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastasic prostate cancer: initial findings of PET with 2-Deoxy-2-[F-18]fluoro-D-glucose. Radiology 1996;199:751-6.
16. Steinert HC, Huch-Böni RA, Buck A, Böni R, Berthold T, Marincek B, Burg G, von Schulthess GK. Malignant melanoma: staging with whole-body positron emission tomography and 2-(F-18)-Fluoro-2-deoxy-D-glucose. Radiology 1995;195:705-9.
17. Rinne D, Baum RP, Hör G, Kaufmann R. Primary staging and follow-up of high-risk melanoma patients by whole-body F-18-FDG positron emission tomography (PET): results of a prospective study in 100 patients. Cancer 1998;82:1664-71.
18. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, Benoit T, Foidart-Willems J. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996;23:1641-74.
19. Yao WJ, Hoh JA, Glaspy F. Whole-body FDG-PET imaging for staging of malignant melanoma: is it cost effective? J Nucl Med 1994;35:8P.
20. von Shulthess GK, Steinert HC, Dummer R, Weder W. Cost effectiveness of whole-body PET imaging in non-small cell lung cancer and malignant melanoma. Acad Radiol 1998;5(Suppl 2):S300-2.
21. Pounds TR, Valk PE, Haseman MK. Whole-body PET-FDG imaging in diagnosis of metastatic melanoma: comparison to CT [abstract]. J Nucl Med 1995;36:119P.
22. Valk PE, Segall GM, Johnson DL, Pounds TR, Tesar RD, Jadvar H, Abella-Columna E. Cost-effectiveness of whole-body FDG PET imaging in metastatic melanoma. J Nucl Med 1997;38:90P.
23. Reske S. Arbeitsausschuß positronen-emissions-tomographie der DGN: konsensus-onko-PET. Nuklearmedizin 1997;36:45-6.
24. Minn H, Clavo AC, Greenman R, Wahl RL. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med 1995;36:252-8.
25. Bailet JW, Abemayor E, Jabour BA, Hawkins RA, Ho C, Ward PH. Positron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope 1992;102:281-8.
26. Benchaou M, Lehmann W, Slosman DO, Becker M, Lemoine R, Rufenacht D, Donath A. The role of FDG-PET in the pre-operative assessment of N-staging in head and neck cancer. Acta Otolaryngol (Stockh) 1996;116:332-5.
27. Jabour BA, Choi Y, Hoh CK, Rege SD, Soong JC, Lufkin RB, Hanafee WN, Maddhi J, Chaiken L, Bailet J, et al. Extracranial head and neck: PET imaging with 2-[F-18]Fluoro-2-deoxy-D-glucose and MR imaging correlation. Radiology 1993;186:27-35.
28. Rege S, Maass A, Chaiken L, Hoh CK, Choi Y, Lufkin R, Anzai Y, Juillard G, Maddahi J, Phelps ME. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer 1994;73:3047-58.
29. Rege SD, Chaiken L, Hoh CK, Choi Y, Lufkin R, Anzai Y, Juillard G, Maddhi J, Phelps ME, Hawkins RA. Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck: quantitation with PET. Radiology 1993;189:807-12.
30. Minn H, Soini I. [18F]Fluorodeoxyglucose scintigraphy in diagnosis and follow-up of treatment in advanced breast cancer. Eur J Nucl Med 1989;15:61-6.
31. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-(F-18)-fluoro-D-glucose. Radiology 1991;179:765-70.
32. Wahl RL, Kaminski MS, Ethier SP, Hutchins GD. The potential of 2-deoxy-2-(F18)-fluoro-D-glucose (FDG) for the detection of tumor involvement in lymph nodes. J Nucl Med 1990;31:1831-5.
33. Tse NY, Hoh CK, Hawkins RA, Zinner MJ, Dahlburn M, Choi Y, Maddahi J, Brunicardi FC, Phelps ME, Glaspy JA. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992;216:27-34.
34. Khalkhali I, Mena I, Digles L. Review of imaging techniques for the diagnosis of breast cancer: the new role of prone scintimammography using technetium-99m-sestamibi. Eur J Nucl Med 1994;21:357-62.
35. Palmedo H, Schomburg A, Grünwald F, Mallmann P, Krebs D, Biersack HJ. Technetium-99m-MIBI scintimammography for suspicious breast lesions. J Nucl Med 1996;37:626-30.
36. Boring CC, Squires TS, Tong T. Cancer statistics 1993. CA Cancer J Clin 1993;43:7-26.
37. Seppelt U. Validierung verschiedener diagnostischer methoden zur beurteilung des lymphknotenstatus. In: Weißbach L, Bussar-Maatz R (Hrsg), eds. Die diagnostik des ho-dentumors und seiner metastasen. Basel, Switzerland: Karger; 1988:154-69.
38. Bender H, Schomburg A, Albers P, Palmedo H, Menzel F, Klemm E, Grünwald F, Ruhlmann J, Müller SC, Biersack HJ. Grenzen von Ganzkörper-FDG-PET beim staging von Hoden-Tumoren. Nuklearmedizin 1996;35:A54.
39. Reinhardt M, Müller-Mattheis V, Vosberg H, Ackermann R, Müller-Gärtner HW. Staging retroperitonealer lymphknoten bei hodenkrebs mit FDG-PET. Nuklearmedizin 1997;36:A33.
40. Cremerius U, Adam G, Zimny M, Jakse G, Büll U. Vergleich von FDG-PET, CT, und tumormarkern beim hodentumor-staging. Nuklearmedizin 1998;37:A10.
41. Valk PE, Pounds TR, Hopkins DM, et al. Staging lung cancer by whole-body PET-FDG imaging [abstract]. J Nucl Med 1995;36:96P.
42. Lewis K, Griffin S, Mardsen P, Gee T, Nunan T, Malsey M, Dussek J. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994;344:1265-6.
43. Valk PE, Pounds TR, Hopkins DM, Haseman MK, Hofer GA, Greiss HB, Myers RW, Lutrin CL. Staging lung cancer by PET imaging. Ann Thor Surg 1995;60:1573-82.
44. Dewan NA, Gupta NC, Redepenning LS, Phalen JJ, Frick MP. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. Chest 1993;104(4):997-1002.
45. Salathe M, Soler M, Bolliger CT, Dalquen P, Perruchoud AP. Transbronchial needle aspiration in routine fiberoptic bronchoscopy. Respiration 1992;59:5-8.
46. Wang KP, Kelly SJ, Britt JE. Percutaneous needle aspiration biopsy of chest lesions. New instrument and new technique. Chest 1988;93:993-7.
47. Winning AJ, McIvor J, Seed WA, Husain OA, Metaxas N. Interpretation of negative results in fine needle aspiration of discrete pulmonary lesions. Thorax 1986;41(11):875-9.
48. Chin R Jr, Ward R, Keyes JW, Choplin RH, Reed JC, Wallenhaupt S, Hudspeth AS, Haponik EF. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Respir Crit Care Med 1995;152:2090-6.
49. Gupta NC, Frank AR, Dewan NA, Redepenning LS, Rothberg ML, Mailliard JA, Phalen JJ, Sunderland JJ, Frick MP. Solitary pulmonary nodules: detection of malignancy with PET with 2-(F-18)-Fluoro-2-deoxy-D-glucose. Radiology 1992;184:441-4.
50. Gupta NC, Dewan NA, Frank A. Diagnostic evaluation of suspected solitary nodules (SPN) using PET FDG imaging. Chest 1993;104:119S.
51. Kubota K, Matsuzawa T, Fujiwara T, Ito M, Hatazawa J, Ishiwata K, Iwata R, Ido T. Differential diagnosis of lung tumors with positron emission tomography: a prospective study. J Nucl Med 1990;31(12):1927-32.
52. Patz EF Jr, Lowe VJ, Hoffman JM, Paine SS, Burrowes P, Coleman RE, Goodman PC. Focal pulmonary abnormalities: evaluation with F-18-fluorodeoxyglucose PET scanning. Radiology 1993;188(2):487-90.
53. Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner P, Valk P, Karis J, Hübner K, Delbeke D, Heiberg EV, Patz EF, Coleman RE. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998;16:1075-84.
54. Steinert HC, Hauser M, Allemann F, Engel H, Berthold T, von Schulthess GK, Weder W. Non-small cell lung cancer: nodal staging with FDG-PET versus CT with correlative lymph node mapping and sampling. Radiology 1997;202:441-6.
55. Bury T, Dowlati A, Paulus P, Hustinx R, Radermecker M, Rigo P. Staging of non-small cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography. Eur J Nucl Med 1996;23:204-6.
56. Valk PE, Pounds TR, Tesar RD, Hopkins DM, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG-PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994;191:371-7.
57. Strauss LG. Die Positronen-Emissions-Tomographie in der onkologischen therapiekon-trolle. Nuklearmediziner 1996;19:281-5.
58. Hebert ME, Lowe VJ, Hoffmann JM, Patz EF, Anscher MS. Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings. Am J Clin Oncol 1996;19:416-21.
59. Schlag P, Lehner B, Strauss LG, Georgi P, Herfarth C. Scar or recurrent rectal cancer. Positron emission tomography is more helpful for diagnosis than immunoscintigraphy. Arch Surg 1989;124:197-200.
60. Strauss LG, Clorius JH, Schlag P, Lehner B, Kimmig B, Engenhart R, Marin-Grez M, Helus F, Oberdorfer F, Schmidlin P. Recurrence of colorectal tumors: PET evaluation. Radiology 1989;170:329-32.
61. Ito K, Kato T, Tadokorro M, Ishiguchi T, Oshima M, Ishigaki T, Sakuma S. Recurrent rectal cancer and scar: differentiation with PET and MR imaging. Radiology 1992;182:549-52.
62. Schiepers C, Penninchx F, Merckx E. Total body PET imaging of recurrent recto-sigmoid cancer with 18F-FDG [abstract]. J Nucl Med 1993;34:222P.
63. Falk PM, Gupta NC, Thorson AG, Frick MP, Boman BM, Christensen MA, Blatchford GJ. Positron emission tomography for pre-operative staging of colorectal carcinoma. Dis Colon Rectum 1994;37:153-6.
64. Ruhlmann J, Schomburg A, Bender H, Oehr P, Robertz-Vaupel GM, Vaupel H, Wolter H, Kozak B, Biersack HJ. Fluorodeoxyglucose whole body positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum 1997;40:1195-204.
65. Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996;23:737-43.
66. Feine U, Lietzenmayer R, Hanke JP, Wohrle H, Muller-Schauenburg W. 18-FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of F-18-FDG and 131I. Nuklearmedizin 1995;34:127-34.
67. Braams JW, Pruim J, Freling NJM, Nikkels PG, Roodenburg JL, Boering G, Vaalburg W, Vermey A. Detection of lymph node metastases of squamous-cell cancer of head and neck with FDG-PET and MRI. J Nucl Med 1995;36:211-6.
68. Laubenbacher C, Block T, Avril N. Lymph node status in patients with testicular cancer: assessment by F-18 FDG PET [abstract]. Eur J Nucl Med 1995;22:888.
69. Kau RJ, Alexiou C, Laubenbacher C, Ziegler S, Schwaiger M, Arnold W. Positron emission tomography (PET) for the preoperative staging of head and neck tumours. Br J Cancer 1998;77:12.